NexImmune, Inc.: restructuring charge — NexImmune board approves dissolution plan and reduction-in-force of substantially all employees

NexImmune, Inc.

Board unanimously approved liquidation and dissolution, subject to stockholder approval, on November 2, 2023.
Reduction-in-force of substantially all employees approved October 31, 2023; only key management retained for wind-down.
Company will call a special stockholder meeting to vote on dissolution; proxy materials to be filed.
Reduction-in-force expected to be substantially complete in November 2023; cost estimate not yet determinable.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

NexImmune, Inc. announced a restructuring affecting the Company (liquidation and wind up) (substantially all of the Company’s employees).

Type: restructuring
Affected area: the Company (liquidation and wind up)
Headcount: substantially all of the Company’s employees

Exact text from the filing

On October 31, 2023, the Board also approved a reduction-in-force of substantially all of the Company’s employees, other than key members of management necessary to implement the wind up and support the efforts to maximize the value of the business and its assets.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-269502

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.